SANA SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Investigates Sana Biotechnology, Inc. (NASDAQ: SANA) Following Significant Price Decline

SANA Investor Alert: Bronstein, Gewirtz & Grossman LLC Announces Investigation into Sana Biotechnology, Inc.

NEW YORK, March 25, 2023-- Bronstein, Gewirtz & Grossman LLC is investigating potential claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) concerning the Company's possible violations of federal securities laws.

On March 23, 2023, the Company announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") regarding its Biologics License Application ("BLA") for SANA001, an investigational treatment for amyotrophic lateral sclerosis ("ALS"). The FDA's letter raised concerns regarding the Company's manufacturing process and the potential for contamination.

The investigation focuses on whether the Company and certain of its officers and directors made false and/or misleading statements and/or failed to disclose material information, in violation of federal securities laws. Specifically, the investigation is looking into whether the Company's statements regarding the development and testing of SANA001, as well as its manufacturing process and quality control measures, were false or misleading.

Those who purchased Sana Biotechnology, Inc. securities and suffered a loss are encouraged to contact Bronstein, Gewirtz & Grossman LLC to discuss their legal rights and options. The investigation is ongoing and there is no assurance that any wrongdoing will be found or that any claims will be filed.

About Bronstein, Gewirtz & Grossman LLC Bronstein, Gewirtz & Grossman LLC is a law firm that specializes in securities litigation and class action matters. The firm has successfully handled numerous securities class action cases involving various publicly traded companies, including those in the biotechnology industry.